Clinical trial · Observational
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig
Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig by Early Adopters
NCT07636863CI-TRIAL-00114061completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will review medical records of adults with cancer who received nivolumab either as an intravenous (IV) infusion or as a subcutaneous (under the skin) injection in community oncology clinics in the United States. The study will describe who receives each type of treatment, how the treatments are used, and selected safety events such as reactions at the injection or infusion site and infections.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
| Subcutaneous nivolumab combined with hyaluronidase | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- IV Nivolumab
- description
- Participants who receive intravenous (IV) nivolumab in community oncology settings.
- interventionNames
- Drug: Nivolumab
- label
- SC Nivolumab + Hyaluronidase
- description
- Participants who receive subcutaneous (SC) nivolumab combined with hyaluronidase
- interventionNames
- Combination Product: Subcutaneous nivolumab combined with hyaluronidase
Primary outcomes (16)
- measure
- Participant age
- timeFrame
- Baseline
- measure
- Participant sex
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Are ≥ 18 years of age at the index date * Have a confirmed cancer diagnosis * Received one of the following treatments: * Intravenous (IV) nivolumab * Subcutaneous (SC) nivolumab + hyaluronidase Exclusion Criteria: * Currently receiving a clinical trial therapy at index * Currently receiving treatment for another active concurrent primary cancer diagnosis * Received IV nivolumab or SC nivolumab + hyaluronidase off-label
References
Publications (0)
Data not yet available
No reference posted for this study.